Recovered COVID-19 patients likely protected for at least 6 months, study finds | Inquirer News

Recovered COVID-19 patients likely protected for at least 6 months, study finds

/ 12:23 PM February 03, 2021

LONDON — Almost all people previously infected with COVID-19 have high levels of antibodies for at least six months that are likely to protect them from reinfection with the disease, results of a major UK study showed on Wednesday.

Scientists said the study, which measured levels of previous COVID-19 infection in populations across Britain, as well as how long antibodies persisted in those infected, should provide some reassurance that swift cases of reinfection will be rare.

“The vast majority of people retain detectable antibodies for at least six months after infection with the coronavirus,” said Naomi Allen, a professor and chief scientist at the UK Biobank, where the study was carried out.

Article continues after this advertisement

Among participants who had tested positive for previous COVID-19 infection, 99% retained antibodies to SARS-CoV-2 for three months, the results showed. After the full six months of follow-up in the study, 88% still had them.

FEATURED STORIES

“Although we cannot be certain how this relates to immunity, the results suggest that people may be protected against subsequent infection for at least six months following natural infection,” Allen said.

She said the findings were also consistent with results of other studies in the United Kingdom and Iceland which found that antibodies to the coronavirus tended to persist for several months in those who have had the disease and recovered.

Article continues after this advertisement

A study of UK healthcare workers published last month found that people who have had COVID-19 were likely to be protected for at least five months, but noted that those with antibodies may still be able to carry and spread the virus.

Article continues after this advertisement

The UK Biobank study also found that the proportion of the UK population with COVID-19 antibodies – a measure known as seroprevalence – rose from 6.6% at the start of the study period in May/June 2020 to 8.8% by November/December 2020.

SARS-CoV-2 seroprevalence was most common in London, at 12.4%, and least common in Scotland at 5.5%, it found.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: antibodies, Coronavirus, COVID-19, UK Biobank

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.